Hot Topic

Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation

Robert L. Ferris a,⇑, Heinz-Josef Lenz b, Anna Maria Trotta c, Jesús García-Foncillas d, Jeltje Schulten e, François Audhuy f, Marco Merlano g, Gerard Milano h,⇑

a Department of Otolaryngology, University of Pittsburgh Cancer Institute, University of Pittsburgh, 5117 Centre Avenue, Suite 2.26, Pittsburgh, PA 15213, United States
b Division of Medical Oncology, University of Southern California Norris Cancer Center, Los Angeles, CA, United States
c Immunology Unit, Functional Genomics, Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione Giovanni Pascale", Naples, Italy
d Cancer Institute, "Fundación Jiménez Díaz" University Hospital, Autonomous University, Madrid, Spain
e Merck KGaA, Darmstadt, Germany
f Merck Santé SAS and Merck Serono SAS, 37 rue Saint-Romain 69008, Lyon, France
g Department of Medicine, Head Clinical Oncology and Translational Research, S. Croce and Carle University Teaching Hospital and ARCO Foundation, via M. Cippolino 26, 12100 Cuneo, Italy
h Oncopharmacology Unit, Centre Antoine Lacassagne, 33 Avenue Valombreuse, 06189 Nice Cedex 2, France

A R T I C L E   I N F O

Article history:
Received 21 August 2017
Received in revised form 17 November 2017
Accepted 18 November 2017

Keywords:
ADCC
Cetuximab
CTLA-4
PD-L1
PD-1
Immunotherapy

A B S T R A C T

Immunoglobulin (Ig) G1 antibodies stimulate antibody-dependent cell-mediated cytotoxicity (ADCC). Cetuximab, an IgG1 isotype monoclonal antibody, is a standard-of-care treatment for locally advanced and recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and metastatic colorectal cancer (CRC). Here we review evidence regarding the clinical relevance of cetuximab-mediated ADCC and other immune functions and provide a biological rationale concerning why this property positions cetuximab as an ideal partner for immune checkpoint inhibitors (ICIs) and other emerging immunotherapies. We performed a nonsystematic review of available preclinical and clinical data involving cetuximab-mediated immune activity and combination approaches of cetuximab with other immunotherapies, including ICIs, in SCCHN and CRC. Indeed, cetuximab mediates ADCC activity in the intratumoral space and primes adaptive and innate cellular immunity. However, counterregulatory mechanisms may lead to immunosuppressive feedback loops. Accordingly, there is a strong rationale for combining ICIs with cetuximab for the treatment of advanced tumors, as targeting CTLA-4, PD-1, and PD-L1 can ostensibly overcome these immunosuppressive counter-mechanisms in the tumor microenvironment. Moreover, combining ICIs (or other immunotherapies) with cetuximab is a promising strategy for boosting immune response and enhancing response rates and durability of response. Cetuximab immune activity—including, but not limited to, ADCC—provides a strong rationale for its combination with ICIs or other immunotherapies to synergistically and fully mobilize the adaptive and innate immunity against tumor cells. Ongoing prospective studies will evaluate the clinical effect of these combination regimens and their immune effect in CRC and SCCHN and in other indications.

© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

In recent years, emerging tools for targeting tumor cells via the immune system have shifted oncologists’ focus away from cyto-

toxic chemicals and onto immunotherapy. Almost all of the functions of the immune system may have therapeutic implications, and many have already been widely studied in experimental models and in humans. Among them, antibody-dependent cell-mediated cytotoxicity (ADCC) appears to be a promising field of investigation.

Years of preclinical and clinical work have shown that immunoglobulin (Ig) G1 monoclonal antibodies (mAbs) have the highest capability for stimulating ADCC compared with other

* Corresponding authors at: Centre Antoine Lacassagne, 33 Avenue Valombreuse, 06189 Nice Cedex 2, France (G. Milano); UPMC Hillman Cancer Center, 5117 Centre Avenue, Suite 2.26, Pittsburgh, PA 15213, United States (R.L. Ferris).
E-mail addresses: ferrrl@UPMC.EDU (R.L. Ferris); merlano.m@pedale.cuneo.it (M. Merlano); gerard.milano@nice.unicanter.fr (G. Milano).

https://doi.org/10.1016/j.ctrv.2017.11.008
0305-7372/© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Mechanism of cetuximab-driven immune activity

ADCC is a biological process that contributes to the targeting and killing of antibody-coated cells by immune cells and is triggered by IgG1 isotype mAbs in the presence of natural killer (NK) cells. Cetuximab has strong immunomodulatory activity, in part via ADCC, in addition to inhibition of the EGFR intracellular signaling pathway [17–20]. Briefly, cetuximab stimulates ADCC when its constant region, Fc, binds to a receptor found on NK cells (activating Fc receptor CD16/FcγRIII) [21], resulting in NK cell activation. Active NK cells can carry out their own lytic activity on tumor cells, and each active NK cell can serially lyse multiple target cells [22]. This is the process of ADCC. Importantly, other immune activity also results from the activation of NK cells via the interaction with the Fc region of an IgG1 isotype mAb. NK cells appear to use interferon-γ (IFNγ) and various cytokines to facilitate crosstalk with dendritic cells (DCs) and other immune cells (eg, macrophages, other NK cells). Activated NK cells that lyse tumor cells lead to the release of tumor antigens, which can be cross-

![Diagram](image.png)

**Fig. 1.** Rationale for combination therapy. Complementary and synergistic activities of cetuximab and ICI-based therapies. This Venn diagram describes the known advantages (in black) and challenges (in red) associated with the use of cetuximab and ICIs. The two therapies have complementary properties (eg, when considering TTR and mobilization of Treg), and thus, the combination of cetuximab and ICIs may yield high levels of immunostimulation and a durable response in a high percentage of patients. ADCC, antibody-dependent cell-mediated cytotoxicity; EGFR, epidermal growth factor receptor; ICI, immune checkpoint inhibitor; NK, natural killer; ORR, overall response rate; PD-L1, programmed death-ligand 1; RR, response rate; Treg, regulatory T cells; TTR, time to response. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
presented by DCs to cytotoxic T cells, priming them for additional tumor cell killing activity [19,23–28]. Thus, the binding of an IgG1 isotype mAb to its target and to the CD16 receptor on NK cells can stimulate the priming and activation of both immune effector cells of the innate and adaptive immune systems. Additionally, cytokine-mediated crosstalk with macrophages and other immune cells is essential for bringing into the intratumoral space additional active, cytotoxic T cells, which can then carry out lytic activity on tumor cells and thus generate additional tumor antigens and further stimulate a long-term immune response [29,30]. Thus, cetuximab stimulates immunogenic tumor cell death, involving multiple cytotoxic immune cell types [29,30]. An overview of the mechanisms for mounting a cetuximab-driven, antitumor immune response is shown in Fig. 2A, and current preclinical and clinical evidence for cetuximab-driven ADCC and other mechanisms is summarized in Tables 1 and 2.

Cetuximab elicits tumor cell apoptosis via EGFR inhibition and additional tumor cell death mediated by the distinct mAb-dependent immune actions (cytotoxic T cell recruitment and priming), including mechanisms specific to its IgG1 backbone (NK cell-mediated ADCC) [6,24,31–33]. The existence of an IgG2 isotype anti-EGFR mAb, panitumumab (which does not trigger NK cell–mediated ADCC), has offered researchers the unique opportunity to compare the effects of mAb-mediated EGFR inhibition +/- the attribute of NK cell stimulation. The immunologic distinction between these 2 mAbs has been conclusively demonstrated ex vivo: when all other conditions are equal and optimized, an IgG1 anti-EGFR mAb (cetuximab) stimulates NK cell–mediated ADCC and thus increases immune-mediated tumor cell death to a greater level than does an IgG2 anti-EGFR mAb [19,29,31,34]. This difference in activity may account for the differential efficacy of the 2 mAbs sometimes observed in human patients; for example, in
Clinical trials, cetuximab has measurable antitumor activity (resulting in overall survival benefits) in SCCHN in combination with radiotherapy or platinum-based chemotherapy, while panitumumab was not able to demonstrate a statistically positive difference [35–38]. Tumor-antigen binding (i.e., to EGFR) and ADCC stimulation are interlinked processes, a phenomenon that may explain why ADCC appears highly relevant for antitumor efficacy and that ADCC is an important component of cetuximab’s antitumor activity; more generally, studies suggest that ADCC measurement, including the mechanism of ADCC; discussion follows. Indeed, this may be the case for other indications with high tumor EGFR expression, such as lung cancer [39], or for any patient with cancer who has high basal ADCC activity [2,40].

Experimentally, ex vivo and in vitro assays with patients’ purified lymphocyte populations [3,19,25,26,41] from the tumor microenvironment and the peripheral blood are directly observable NK cell activation and lytic activity [31,42,43]. Indirect measurements are performed using markers on circulating and tumor-infiltrating T cells, NK cells, and DCs, as well as cytokine levels in the plasma [1,44], including expression of activating receptors such as CD16, CD107a, CD137, NK group 2 member D (NKGD2), and NK cell p46–related protein (NKp46) receptors [26,42,45]. Furthermore, expression of perforin and granzyme B, the functional molecules of NK cell lytic activity, also indicates high tumor cell killing, and their depletion can lead to the eventual dampening of lytic activity [22,42,45]. Conversely, increased levels of transforming growth factor β (TGFβ) or interleukin 10 (IL-10) in plasma, increased expression of CTLA-4 and PD-1 on T cells, PD-1-mediated activity; more generally, studies suggest that ADCC measurement, monitoring, and targeting are of clinical importance during cancer treatment of individual patients with IgG1 isotype mAbs [5,31].

Markers for ADCC and related immune responses

Biological differences between tumor types can be overshadowed by the individual intervariability seen among patients with a given tumor type based on factors such as disease stage, age, genetic markers, and tumor biomarker expression. Individual ADCC activity and CD16 receptor alleles may be predictive for clinical outcomes in response to IgG1-based anticancer therapy.

Table 1
Preclinical evidence for cetuximab-mediated immune effects.

<table>
<thead>
<tr>
<th>Relevant findings</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ji et al.: In ex vivo assays, ipilimumab can suppress CTLA-4+ Treg activity and restore cetuximab-driven, NK cell–mediated ADCC [42]</td>
<td>SCCHN</td>
</tr>
<tr>
<td>Khor et al.: Cetuximab treatment is associated with increased expression of CD137 on isolated human NK cells; treating with a CD137–agonistic mAb in addition to cetuximab led to increased cytotoxicity. Treating with this combination therapy led to complete tumor resolution in a murine xenograft model [60]</td>
<td>CRC</td>
</tr>
<tr>
<td>Kubat et al.: High-dose IgG1 anti–EGFR antibodies induce immune-independent tumor regression, but at low doses, they induce tumor cell killing through CD8+ T cell–mediated ADCC [115]</td>
<td>SCCHN</td>
</tr>
<tr>
<td>Trivedi et al.: Panitumumab and cetuximab inhibit the EGFR to a similar extent; however, cetuximab is more effective at triggering NK cell–mediated ADCC [19]</td>
<td>SCCHN</td>
</tr>
<tr>
<td>Trotta et al.: Patients carrying the CD16 genotypes 158 V/V and 158 F/V experienced significantly higher ADCC activity after cetuximab treatment than did patients carrying the 158 F/F genotype. Additionally, patients carrying the V allele had longer PFS than patients who did not, although no significant difference in OS was observed [3]</td>
<td>CRC</td>
</tr>
<tr>
<td>Yang et al.: Cetuximab antitumor activity is more potent in the presence of adaptive immunity components, including CD8+ T cells [116]</td>
<td>SCCHN</td>
</tr>
<tr>
<td>ADCC mechanism</td>
<td></td>
</tr>
<tr>
<td>Chen et al.: In a murine xenograft model, cetuximab increased NK cell–mediated ADCC activity against colorectal cancer cells with high EGFR expression [117]</td>
<td>CRC</td>
</tr>
<tr>
<td>Correale et al.: 5-FU, irinotecan, and gemcitabine individually and in combination can induce increased EGFR expression in colorectal tumor cells and increase susceptibility to cetuximab-driven ADCC [118]</td>
<td>CRC</td>
</tr>
<tr>
<td>Levy et al.: HLA-E can inhibit cetuximab-driven ADCC and thus interfere with cetuximab-driven immune cell–mediated lytic activity against tumor cells [119]</td>
<td>CRC</td>
</tr>
<tr>
<td>ADCC modulation</td>
<td></td>
</tr>
<tr>
<td>Kondo et al.: EGFR expression levels on tumor cells may influence sensitivity to cetuximab-driven ADCC [120]</td>
<td>SCCHN</td>
</tr>
<tr>
<td>Nakadate et al.: Cetuximab-driven, perfom-independent ADCC was observed against colorectal cancer cells only when they have wild-type Kras status [121]</td>
<td>CRC</td>
</tr>
<tr>
<td>Taylor et al.: Cetuximab-driven ADCC can kill SCCHN cells in vitro, and is highest in patients carrying a V allele at position 158 on CD16 [122]</td>
<td>CRC</td>
</tr>
<tr>
<td>Veluchamy et al.: Cetuximab enhances NK cell–mediated lytic activity on EGFR-expressing tumor cells in a CD16–, but not RAS mutational status–dependent manner [43]</td>
<td>CRC</td>
</tr>
<tr>
<td>Seo et al.: Cetuximab enhances peripheral mononuclear cell–mediated ADCC on EGFR-expressing tumor cells independently of RAS or BRAF mutational status–dependent manner [123]</td>
<td>CRC</td>
</tr>
<tr>
<td>Srivastava et al.: Cetuximab in combination with CD137 agonist mAb urelumab led to increased NK cell survival, DC maturation, and tumor antigen cross-presentation in patients in a phase 1b study [44]</td>
<td>SCCHN</td>
</tr>
</tbody>
</table>
studies suggest that increasing the binding affinity of the Fc region intermediate between V/V and F/F or equal to V/V, depending on SGCN. Clin Cancer Res 2016; pii: clin.cancers.1934.2016.


Rocca et al. Phenotypic and functional dysregulated blood NK cells in colorectal cancer patients can be activated by cetuximab plus IL-2 or IL-15. Front Immunol 2016;7:413


Direct link between ADCC and treatment outcomes


Jie et al. CTLA-4+ regulatory T cells are increased in cetuximab treated head and neck cancer patients, suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res 2015;75:2200–10


Lattanzio L. 33 patients having a mutation in KRAS, NRAS, BRAF, (suspected choice that could have confounded the results) concluded that neither the CD32A nor the CD16 polymorphisms are predictive of baseline ADCC and EGFR expression can have a positive correlation with the rate of complete responses in patients with LA SGCN who are treated with cetuximab and radiotherapy [40]. Also possibly having an effect on baseline ADCC activity are KRAS mutations (although data are conflicting with regard to directionality) [31,51,52], presence of disease (healthy volunteers mount a greater response than cancer patients), and polymorphisms in the CD32A and CD16 Fc receptors [31,33,53,54]. Because increased ability to mount an ADCC response tends to correlate with prolonged overall survival [3,33], it is important that these differences be understood and used to potentially guide personalized treatment decisions. Such information is especially crucial in the first line, when the immune system may be best poised to mount an antitumor response (given that immune depletion often occurs following chemotherapy) [55]. As of this writing, the CD16 polymorphism is the best-studied biomarker for ADCC.

CD16 is not required for endogenous NK cell–mediated tumor cell lysis, but it is necessary for IgG1-mediated ADCC [33,56], and studies suggest that increasing the binding affinity of the Fc region to CD16 can increase NK cell cytotoxic activity [57,58]. A CD16 Fc receptor that has a valine (V) at codon 158 (vs a phenylalanine [F]) has a much higher binding affinity for mAbs. Therefore, patients who carry the V/V polymorphism are more immunologically responsive to IgG1 isotype mAb-based therapy (cetuximab, rituximab, trastuzumab, etc) than patients with the F/F polymorphism; the V/F variant appears to manifest as an affinity phenotype that is intermediate between V/V and F/F or equal to V/V, depending on the study [33,49,50,53,54,59]. Downstream of CD16 activation, CD137 expression (which stimulates recruitment of EGFR-specific cytotoxic T cells to the tumor) correlated with clinical response [44,60]. Interestingly, in an analysis of 107 patients with SGCN who received cetuximab, no predictive value for CD16 codon 158 polymorphism was detected for anti-EGFR therapy efficacy (although only 13 patients had the V/V variant); another study in 49 patients with KRAS wild-type mCRC found a significant difference in outcomes among patients with different genetic variants of CD16 [26,61]. Therefore, the predictive value of CD16 remains to be fully confirmed.

An additional polymorphism associated with cetuximab immune activity is found on codon 131 (histidine [H] vs arginine [R]) of the CD32A/FcγRIIa receptor on DCs and neutrophils [25]; this polymorphism helps restore tumor immune surveillance and stimulates downstream immunogenic response. The 6-month disease control rate (DCR) was higher in patients with CRC (n=47) treated with cetuximab and carrying the H/H and H/R variants (67% and 50%, respectively) vs the R/R variant (17%), despite all patients having a mutation in KRAS, NRAS, BRAF, or PI3K (suspected to confer resistance to cetuximab in CRC). In the same study, patients carrying the V/V or V/F variant on CD16 (31 patients; 70% of the overall study population) had a combined 6-month DCR of 52% vs 23% in patients carrying the F/F variant (n=13) [62]. Similarly, in patients with mCRC treated with cetuximab plus irinotecan–based chemotherapy, overall survival was significantly longer in patients carrying a 158 V genotype [63]. A meta-analysis of studies of anti-EGFR mAb-based therapy in CRC (that did not distinguish between cetuximab and panitumumab, a choice that could have confounded the results) concluded that neither the CD32A nor the CD16 polymorphisms are predictive of response during therapy [64]. It should be noted that IgG2-
Driven immune activity may be associated with polymorphisms on CD32A [65]. Indeed, it appears that any effect of CD32A polymorphisms on baseline ADCC activity is due to linkage disequilibrium rather than direct interaction [66]. Further investigation is required to fully characterize the predictive value of CD16/32 receptor polymorphisms during immunomodulatory therapy.

Treg and other immunosuppressive mechanisms are triggered in the intratumoral space as feedback mechanisms to counteract cytotoxic tumor cell lysis [42,48,67–71]. These negative regulatory mechanisms, detailed in the next section, could become additional therapeutic targets when planning combination treatments with cetuximab.

Immunosuppressive mechanisms that can account for the dampening of cetuximab-mediated immune activity. Immunostimulatory activity initiated by the binding of cetuximab to EGFR and to the CD16 receptor on NK and dendritic cells sets off feedback immunosuppressive mechanisms, including Treg tumor infiltration and expression of immune checkpoints on tumor and immune cells. CD, cluster of differentiation; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; CXCL, chemokine (C-X-C motif) ligand; CXCR, C-X-C chemokine receptor; EGFR, epidermal growth factor receptor; HLA, human leukocyte antigen; IFNγ, interferon-γ; IL, interleukin; MDSC, myeloid-derived suppressor cell; NK, natural killer; PD-1, programmed death receptor 1; PD-L1, programmed death-ligand 1; TGFβ, transforming growth factor β; Treg, regulatory T cells.

**Treg**

An overview of the immunosuppressive pathways activated in response to cetuximab-mediated immunostimulation in the tumor microenvironment is presented in Fig. 2B [42,48,67–71]. Treg activity is one of the most powerful immunosuppressive mechanisms in the intratumoral space. Compared with those of healthy subjects, cancer patients’ peripheral blood and tumor-infiltrating lymphocyte populations are enriched in Treg, possibly due to con-
version from Foxp3- to Foxp3+ in response to increased TGFβ signaling (based on preclinical and ex vivo studies) [48,67,68,72,73]. Treg secrete suppressive cytokines and express membrane-bound TGFβ, thus inhibiting the cytolytic activity of T cells and NK cells, as well as the maturation of DCS [42,68]. Furthermore, highly immunosuppressive Foxp3+/CTLA-4+ or PD-L1+ Treg are found to be more concentrated in the tumor microenvironment than in the peripheral blood [48]. In the presence of increased CD4+ /CD25hi/Foxp3+ Treg populations in the intratumoral space, NK cells have lowered expression of biomarkers indicative of ADCC activity, such as granzyme B, perforin, and CD16 [42,46]. In vitro and ex vivo assays demonstrate that the addition of CD4+/CD25hi/Foxp3+ Treg suppress cetuximab-driven NK-mediated ADCC in patients with SCCHN via secreted cytokines and membrane-bound TGFβ; TGFβ inhibitors are sufficient to block this Treg-mediated immune suppression in vitro [42,46,68,70,71]. Crucially, in vitro experiments and a phase 1a clinical trial suggest that depleting the CD4+/Foxp3+ Treg population can restore or enhance NK cell cytotoxic activity [68,74,75].

Furthermore, it is conceivable that Treg-mediated suppression of cetuximab-driven immune activity can potentially be a prognostic factor in patients undergoing treatment with cetuximab for LA SCCHN. Cetuximab plus chemotherapy/radiotherapy treatment in patients with LA SCCHN (n = 22) led to a significant increase in the frequency of CD4+/Foxp3+ Treg within lymphocyte populations in both the peripheral blood and tumor microenvironment [42]. Furthermore, 4 weeks of cetuximab monotherapy (n = 18 patients) appeared to increase the frequency of intratumoral CD4+/Foxp3+ Treg expressing markers of immunosuppression such as CTLA-4, CD39, and membrane-bound TGFβ. Peripheral CD4+/Foxp3+ Treg were significantly enriched in CTLA-4, possibly indicating a response to cetuximab-driven immunostimulation (and by extension the conversion of an immunologically “cold” tumor to a “hot” phenotype) [25,42]. When comparing the frequency of Treg in both the periphery and the intratumoral space in clinical responders to cetuximab with that of nonresponders, Jie et al. found that responders have stable Treg populations, while nonresponders have significant increases in CTLA-4+ Treg within both the peripheral blood and tumor-infiltrating lymphocyte populations [42]. Similar observations regarding the correlation between Treg recruitment to the tumor microenvironment and lower patient survival have been made across multiple tumor types [72,76]. Interestingly, specifically in CRC, tumor-infiltrating Treg can have high (suppressive) vs low (nonsuppressive) Foxp3 expression, and the presence of the latter may be a positive prognostic biomarker of immune response [77]. Overall, it appears that cetuximab-driven ADCC and other immune activity initiate a negative feedback loop of immunosuppression via immune checkpoints; thus, inhibition of suppressive Treg (eg, CTLA-4+ or PD-L1+ populations) through ICI treatment is a logical therapeutic strategy to use in combination with cetuximab in both SCCHN and CRC [78]. In addition, experimental data underline the role of the PD-1/PD-L1 axis inhibition in the prevention of the peripherally induced Treg [79] leading to the curtailment of this cell population into the tumor microenvironment. This fact may be of high importance considering that Ghiringhelli et al. showed an inverse relationship between NK cell activation and the extension of the Treg population [68].

Other immunosuppressive mechanisms impacting cetuximab-driven immune activity

Cetuximab monotherapy results in an increased frequency of CD107α+ and CD137+ (ie, active) NK cells in the tumor microenvironment of patients with SCCHN. Interestingly, cetuximab monotherapy also leads to an increased frequency of circulating vs tumor-infiltrating perforin+ and granzyme B+ NK cells [42]. As perforin and granzyme B are the operative molecules of NK cell lytic activity [45], these findings suggest that additional immunosuppressive mechanisms are ongoing in the intratumoral space and that these mechanisms prevent NK cells in the intratumoral space from mounting degranulation and tumor cell lysis. These immunosuppressive processes are likely therapeutically targetable in a way that would further increase the antitumor effects of cetuximab-mediated immune activity (Fig. 2B). Evidence suggests that suppressive activity also occurs in patients with CRC. For example, the presence of CRC and its increasing stage both correlate with higher levels of NK cells present in the peripheral blood vs the intratumoral space; activating receptors such as NKG2D and NKP46 are decreased in expression on NK cells from patients with CRC vs healthy donors [45]. Blocking the immunosuppressive receptor CD32B on DCS, or incubation with IL-2 or IL-15, has been shown to alleviate some of this inhibition on NK lytic activity [22,25,45], and this strategy may therefore be useful in combination with cetuximab treatment in SCCHN and CRC.

Myeloid-derived suppressor cells (MDSCs) are another cell population considered an important hurdle in immunotherapy [69,80]. Their numbers increase in cancer patients vs healthy volunteers [69], and they encourage tumor immune escape by expressing high levels of TGFβ and producing IL-10 in the tumor microenvironment, its periphery, or the lymph node tissue [81]. Additionally, myeloid-derived cytokines suppress antitumor activity of T cells via C-X-C motif chemokine receptors (CXCR3 and 4, for example) [82,83]. Interestingly, the disinhibition of T cells via anti–PD-1 therapy initiates a negative feedback loop, stimulating myeloid cell production of PD-L1 and subsequent T cell reinhibition [82]. These observations suggest that ICI therapy is a good candidate to counter MDSC-mediated suppression of cytotoxic cells via PD-1/PD-L1 in the tumor microenvironment. Like Treg, MDSC development, expansion, and function can be guided by a variety of factors [84,85].

IFNγ is secreted by NK cells in response to the presence of cells coated with cetuximab and stimulates the maturation of DCS; in addition to priming cytotoxic T cells, DCS reciprocally activate NK cells to induce more IFNγ secretion. The blocking of IFNγ with a neutralizing mAb prevents crosstalk between NK cells and DCS [25,26], revealing potentially relevant mechanisms for immune escape. Incubation of human NK cells in the presence of TGFβ suppresses CD107α-mediated IFNγ secretion, and extended treatment inhibits ADCC via reduction of granymes A and B [86]. In addition, IFNγ can signal via signal transducer and activator of transcription 1 (STAT1) and human leukocyte antigen (HLA) class I to further stimulate cytotoxic T cell activity [87]; defects in this pathway have been associated with impaired T cell–mediated lysis [88], and maintaining HLA class I levels during therapy has been correlated with improved clinical responses to cetuximab-based therapy in patients with SCCHN [87]. Interestingly, EGFR activity aids in tumor immune escape. HLA class I can thus be upregulated via cetuximab’s EGFR-inhibitory activity [87]. Therefore, cetuximab is a logical therapy in that it simultaneously promotes IFNγ secretion and EGFR blockade, both of which are processes that can counteract EGFR-mediated immunosuppression in the tumor microenvironment [87,89,90]. Finally, EGFR signaling and, interestingly, IFNγ aid in tumor immune escape by stimulating PD-L1 expression on tumor cells through the Janus kinase 2 (JAK2)/STAT1 pathway, thus inhibiting active T and NK cells in a PD-1/PD-L1–dependent manner [27,91]. Thus, cetuximab treatment could be useful in potentially priming tumors for better T cell recognition, which would then be enhanced with ICIs.
Optimizing immune action: the promise of combination between cetuximab and immunotherapy

Cetuximab has demonstrated clinically meaningful activity in both SCCHN and RAS wild-type mCRC; it is a vital component of the standard of care for both indications in the unresectable setting, and it yields favorable outcomes in clinical trials and in the real-world setting [35,38,92–95]. Furthermore, cetuximab promotes high response rates as evidenced by its addition to prior standard-of-care treatments (e.g., radiotherapy, chemotherapy), which has led to enhanced ORRs and prolonged survival. In addition to the benefits associated with EGFR inhibition, cetuximab-mediated ADCC and the recruitment and priming of cytotoxic T cells to the intratumoral space are powerful attributes. However, as described above, such immunostimulation is necessarily associated with negative feedback loops (Treg, MDSCs, and increased expression of checkpoint molecules such as PD-1, PD-L1, and CTLA-4). Therefore, co-targeting of these immunosuppressive processes, and the potential synergy between the different mechanisms of action of cetuximab and ICIs, holds the potential to improve patient outcomes in SCCHN and CRC. For example, CTLA-4 or PD-1/PD-L1 blockade has the potential to alleviate Treg- or MDSC-mediated inhibition on both T cells and NK cells, thereby restoring cytotoxic activity and fully mobilizing the adaptive and innate immune systems against tumor cells [96–99], because many of these immunosuppressive mechanisms impinge upon negative regulation of T cells and NK cells via PD-1, PD-L1, or CTLA-4 (Fig. 2C) [13,27,47]. As further evidence in favor of this combination of drugs, cetuximab recruits new immune cells to the tumor microenvironment, whereas ICIs disinhibit cells already present. Thus, cetuximab and ICIs complement each other, and cetuximab could serve to prime the immune system in preparation

Fig. 2C. Mechanisms of synergy between cetuximab and ICIs (or other immunotherapies). ICIs may synergize with cetuximab-driven immune activity by disinhibiting immune effector cells present in the intratumoral space. CD, cluster of differentiation; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; CXCR, C-X-C chemokine receptor; EGFR, epidermal growth factor receptor; IFNγ, interferon-γ; IL, interleukin; MDSC, myeloid-derived suppressor cell; NK, natural killer; PD-1, programmed death receptor 1; PD-L1, programmed death-ligand 1; TGFβ, transforming growth factor β; Treg, regulatory T cells.
for (or counter T cell and NK cell depletion [protective effect] as a result of) ICI therapy, raising the possibility of true synergistic activity via complementary activation of the innate and adaptive immune systems and the engagement of multiple types of immune cells. Although the known safety profiles of cetuximab and ICIs do not appear to overlap, minimal safety and efficacy data are currently available from trials of cetuximab and ICI combinations. Studies assessing acute and late toxicities of cetuximab and ICI combinations are currently ongoing. On the other hand, compounded toxicities has been observed in ICI plus ICI combination treatments, with which additive immune-related adverse events can be severe and may preclude the widespread use of dual-ICI therapy [100,101]. Next, we outline the biological rationale for the combination of cetuximab, a logical combination partner due to its various immunostimulatory effects, with emerging immunotherapies in SCCHN and mCRC (cetuximab’s approved indications for use), placing special focus on ICIs.

Patients with SCCHN are good candidates for powerful immunostimulatory therapy, because such cancers’ possible methods of origin are associated with an immunologically “hot” phenotype [8,13,102–106]. Additionally, the common use of radiotherapy in LA SCCHN provides a unique opportunity to combine the radiosensitizing properties and immunostimulatory activity of cetuximab with T cell dis inhibition as well as the hypothesized absorptive effect with ICIs [21]. Additionally, the combination of cetuximab and avelumab (an anti–PD-L1 IgG1 isotype mAb) is of high interest due to both agents’ ability to stimulate ADCC, because the use of 2 ADCC-inducing mAbs could potentially generate a beneficial immune effect by priming and activating NK cells cooperatively.

Although CRC has traditionally been considered an immunoresistant cancer, prognostic factors such as high basal ADCC activity and the presence of tumor-infiltrating T cells suggest this presumption is inaccurate [224,107]. However, individual tumor molecular subtypes may be differentially susceptible to ICI monotherapy, and thus far only microsatellite-unstable tumors have shown responses to such an approach [108–110], likely because of their tendency to produce neoantigens. Therefore, research into combination therapy with ICIs plus an agent with already-proven activity in mCRC (i.e., cetuximab) is necessary to determine whether such a combination regimen would possess activity in non-microsatellite-unstable tumors.

Consequently, although CRC and SCCHN are very different diseases, cetuximab plus ICIs may still result in additive activity in CRC tumors by priming them for immunotherapy (e.g., by inducing PD-1/PD-L1 expression on immune cells and by recruiting immune effector cells to the tumor). Additionally, cetuximab can mediate increased immune activity within the tumor microenvironment (e.g., drive crosstalk between NK cells and DCs and recruit cytotoxic T cells to the tumor microenvironment) [19,23–28], thus priming the immune system to be more responsive to ICI treatment. Reciprocally, in vitro research on this combination suggests

### Table 3

<table>
<thead>
<tr>
<th>Study</th>
<th>Indication</th>
<th>Arms</th>
<th>Endpoints</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT02764903 (Phase 1)</td>
<td>LA SCCHN</td>
<td>Nivolumab + cisplatin</td>
<td>Dose-limiting toxicity</td>
<td>Radiation Therapy Oncology Group</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nivolumab + high-dose cisplatin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nivolumab + cetuximab</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nivolumab + IMRT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02124850 (Phase 1)</td>
<td>LA SCCHN (stage II–IVA)</td>
<td>Motolimod + cetuximab</td>
<td>Change in immune biomarkers</td>
<td>University of Pittsburgh Medical Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Motolimod + cetuximab + nivolumab</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01860430 (Phase 1b)</td>
<td>LA SCCHN (stage III–IVB)</td>
<td>Cetuximab/IMRT + ipilimumab</td>
<td>Determining starting dose</td>
<td>University of Pittsburgh Cancer Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Clinical response, PFS, potential</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>biomarkers</td>
<td></td>
</tr>
<tr>
<td>NCT01935921 (Phase 1)</td>
<td>High-risk LA SCCHN (stage III–IVB)</td>
<td>Cetuximab/IMRT + ipilimumab</td>
<td>Determining starting dose</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Clinical response, PFS, potential</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>biomarkers, dose response</td>
<td></td>
</tr>
<tr>
<td>NCT02938273 (Phase 1)</td>
<td>LA SCCHN (stage III–IV)</td>
<td>Cetuximab/RT + avelumab</td>
<td>Safety</td>
<td>The Netherlands Cancer Institute</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ORR, changes in tumor</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>microenvironment</td>
<td></td>
</tr>
<tr>
<td>NCT02990887 (Phase 3 REACH trial)</td>
<td>LA SCCHN (stage III–IVB)</td>
<td>Cetuximab/RT + avelumab vs Cisplatin/RT (fit patients) OR cetuximab/RT (unfit patients)</td>
<td>PFS</td>
<td>Groupe Oncologie Radiothérapie</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Tête et Cou</td>
</tr>
<tr>
<td>NCT03051906 (Phase 1b DUCRO HN)</td>
<td>LA SCCHN</td>
<td>Cetuximab/RT + durvalumab</td>
<td>PFS</td>
<td>Azienda Ospedaliero-Universitaria</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Careggi</td>
</tr>
<tr>
<td>NCT02643550 (Phase 1, 2)</td>
<td>Pretreated R/M SCCHN</td>
<td>Cetuximab + monalizumab</td>
<td>Safety</td>
<td>University of Pennsylvania</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ORR</td>
<td></td>
</tr>
<tr>
<td>NCT02318901 (Phase 2)</td>
<td>Advanced SCCHN Advanced mCRC (KRAS/BRAF/NRAS wt)</td>
<td>Pembrolizumab + cetuximab</td>
<td>Determining recommended dose</td>
<td>Western Regional Medical Center/</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Safety</td>
<td>Cancer Treatment Center of America</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ORR, OS, PFS, changes in circulating DNA</td>
<td></td>
</tr>
<tr>
<td>NCT02713373 (Phase 1/2)</td>
<td>Unresectable mCRC (KRAS/BRAF wt)</td>
<td>Pembrolizumab + cetuximab</td>
<td>Safety, PFS, tumor response rate</td>
<td>Roswell Park Cancer Institute</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ORR, OS, changes in blood biomarkers and tumor-immune cell populations</td>
<td></td>
</tr>
<tr>
<td>NCT03174405 (Phase 2)</td>
<td>Untreated mCRC (KRAS/BRAF wt)</td>
<td>Avelumab + cetuximab + FOLFOX</td>
<td>Safety</td>
<td>AIO-Studien-gGmbH</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ORR, PFS, OS, translational research</td>
<td></td>
</tr>
</tbody>
</table>

IMRT, intensity-modulated radiotherapy; LA SCCHN, locally advanced squamous cell carcinoma of the head and neck; mCRC, metastatic colorectal cancer; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; R/M SCCHN, recurrent and/or metastatic squamous cell carcinoma of the head and neck; RT, radiotherapy; wt, wild-type.
that ICIs added to cetuximab can overcome cetuximab resistance, such as that mediated by mutations in RAS and other genes [43].

Although we have focused on ICIs, cetuximab-mediated immune action drives crosstalk with a variety of immune cell types and processes, and therefore it holds the potential for combination with many additional classes of immunotherapy. From ex vivo studies in CRC, combination treatment with cetuximab plus cytokines such as IL-2 or IL-15 was sufficient to restore the lytic activity of patient-derived NK cells to levels comparable to those of healthy donors [45]. Similarly, in SCCHN, cotreatment with cetuximab and urelumab (a CD137-agonist mAb) in a phase 1b trial led to increased levels of granzyme B and NKp46 on NK cells, although there were no changes in IFNγ, PD-1, CD107a, NKG2D, or CD16 [44]. As mentioned earlier in this review, CD137 is a possible marker for clinical response, and urelumab treatment has been shown to lead to increased IFNγ-driven gene expression and cytokine production and overall enhanced immunologic activity [111]. Furthermore, cetuximab in combination with cytokines or urelumab was also able to exert immune activity on EGFR-expressing CRC cell lines or xenograft models despite the presence of a KRAS, NRAS, or BRAF mutation [43,45,60]. Similar observations have been made for cetuximab in triple-negative breast cancer xenografts and KRAS mutant cell lines [112,113].

Additional non-ICI agents currently in clinical trials in combination with cetuximab include monalizumab (IPH2201), an anti-NKG2A mAb that blocks this inhibitory receptor on NK cells in R/M SCCHN (NCT02643550). This combination would stimulate ADCC, inhibit the EGFR, and simultaneously disinhibit NK cells suppressed via TGFβ or IL-10. Motolimod, a toll-like receptor–8 agonist, is being tested in combination with cetuximab for patients with R/M SCCHN (NCT01836029) and has some available early results indicating a DCR of 54% and increases in circulating cytokines [11]. Combination motolimod plus cetuximab with or without nivolumab is now being tested in patients with LA SCCHN (NCT02124850). Other combinations include systemic immunomodulation via heat-killed mycobacteria (IMM-101, NCT03009058), DNA demethylation via valproic acid (NCT02624128) that has been shown to possess antitumor effects in other indications [114], and stimulation of neutrophil growth and activity with granulocyte-colony stimulating factor (NCT02124148). Finally, several trials are investigating ex vivo–grown and –activated immune cells, including NK and CD4+ or CD8+ T cells, in combination with cetuximab (NCT02028455, NCT02507154) across indications. Therapies for additional novel targets, such as CXCR4 activation, MDSC inhibition, and TGFβ traps, will likely compose the next wave of combination therapies. Key ongoing trials of cetuximab and ICI combination therapy in CRC and SCCHN are summarized in Table 3.

Conclusions and future outlook

ICI monotherapy is a new and exciting treatment option, but response rates are modest in some indications, including SCCHN and CRC. Fortunately, there is a strong scientific rationale for combining ICIs and the existing standard-of-care mAb cetuximab for the treatment of advanced SCCHN and CRC. In addition to EGFR inhibition, cetuximab mediates clinically relevant ADCC and other immune activity in the intratumoral space, which is associated with tumor cell killing by components of both the innate and adaptive immune systems. Cetuximab can prime the immune system for ICI therapy by recruiting cytotoxic cell effectors of both the innate and adaptive immune systems to the intratumoral space. Additionally, associated negative feedback loops lead to CTLA-4/PD-1/PD-L1–mediated immunosuppression of active cytotoxic cell types, an issue that ostensibly could be overcome successfully via combination therapy with ICIs. Indeed, in some situations such as non-small cell lung cancer, it has been shown that strong PD-L1 expression is associated with better outcomes when treated with anti–PD-L1. In the case of cetuximab plus avulumab, ongoing prospective studies will evaluate whether using 2 ADCC-inducing mAbs will generate a beneficial immune effect by priming and activating NK cells cooperatively. More generally, by synergistically and fully mobilizing the adaptive and innate immune systems against tumor cells, cetuximab in combination with ICIs or other immunotherapies could hold the key to raising ORRs and durability of response in challenging indications such as SCCHN and CRC. Empirical evidence from currently ongoing clinical trials that are evaluating this hypothesis is eagerly anticipated.

Disclosures

HJL has served on ad boards and provided clinical trial support for Bristol-Myers Squibb and Merck KGaA, Darmstadt, Germany, AMT and JGF have nothing to disclose. MM served on ad boards for Merck KGaA, Darmstadt, Germany, Merck Sharp and Dohme, and Bristol-Myers Squibb and had a speaker role in Merck-promoting meetings.

Acknowledgments

Medical writing assistance was provided by Ina Nikolaeva, PhD, of ClinicalThinking, Inc, Hamilton, NJ, USA, and funded by Merck KGaA, Darmstadt, Germany.

References

[2] Lo Nigro C, Ricci V, Vivenza D, Monteverde M, Strola G, Lucio F, et al. Anticancer activity of the tyrosine kinase inhibitor IM-101 in KRAS mutated cell lines [112,113]. KRAS for cetuximab in triple-negative breast cancer xenografts and DCR of 54% and increases in circulating cytokines [1]. Combination treatment with cetuximab plus or without nivolumab is now being tested in patients with LA SCCHN (NCT02124148). Finally, several trials are investigating ex vivo–grown and –activated immune cells, including NK and CD4+ or CD8+ T cells, in combination with cetuximab (NCT02028455, NCT02507154) across indications. Therapies for additional novel targets, such as CXCR4 activation, MDSC inhibition, and TGFβ traps, will likely compose the next wave of combination therapies. Key ongoing trials of cetuximab and ICI combination therapy in CRC and SCCHN are summarized in Table 3.

Conclusions and future outlook

ICI monotherapy is a new and exciting treatment option, but response rates are modest in some indications, including SCCHN and CRC. Fortunately, there is a strong scientific rationale for combining ICIs and the existing standard-of-care mAb cetuximab for the treatment of advanced SCCHN and CRC. In addition to EGFR inhibition, cetuximab mediates clinically relevant ADCC and other immune activity in the intratumoral space, which is associated with tumor cell killing by components of both the innate and adaptive immune systems. Cetuximab can prime the immune system for ICI therapy by recruiting cytotoxic cell effectors of both the innate and adaptive immune systems to the intratumoral space. Additionally, associated negative feedback loops lead to CTLA-4/PD-1/PD-L1–mediated immunosuppression of active cytotoxic cell types, an issue that ostensibly could be overcome successfully via combination therapy with ICIs. Indeed, in some situations such as non-small cell lung cancer, it has been shown that strong PD-L1 expression is associated with better outcomes when treated with anti–PD-L1. In the case of cetuximab plus avulumab, ongoing prospective studies will evaluate whether using 2 ADCC-inducing mAbs will generate a beneficial immune effect by priming and activating NK cells cooperatively. More generally, by synergistically and fully mobilizing the adaptive and innate immune systems against tumor cells, cetuximab in combination with ICIs or other immunotherapies could hold the key to raising ORRs and durability of response in challenging indications such as SCCHN and CRC. Empirical evidence from currently ongoing clinical trials that are evaluating this hypothesis is eagerly anticipated.

Disclosures

HJL has served on ad boards and provided clinical trial support for Bristol-Myers Squibb and Merck KGaA, Darmstadt, Germany, AMT and JGF have nothing to disclose. MM served on ad boards for Merck KGaA, Darmstadt, Germany, Merck Sharp and Dohme, and Bristol-Myers Squibb and had a speaker role in Merck-promoting meetings.

Acknowledgments

Medical writing assistance was provided by Ina Nikolaeva, PhD, of ClinicalThinking, Inc, Hamilton, NJ, USA, and funded by Merck KGaA, Darmstadt, Germany.

References

[2] Lo Nigro C, Ricci V, Vivenza D, Monteverde M, Strola G, Lucio F, et al. Anticancer activity of the tyrosine kinase inhibitor IM-101 in KRAS mutated cell lines [112,113]. KRAS for cetuximab in triple-negative breast cancer xenografts and DCR of 54% and increases in circulating cytokines [1]. Combination treatment with cetuximab plus or without nivolumab is now being tested in patients with LA SCCHN (NCT02124148). Finally, several trials are investigating ex vivo–grown and –activated immune cells, including NK and CD4+ or CD8+ T cells, in combination with cetuximab (NCT02028455, NCT02507154) across indications. Therapies for additional novel targets, such as CXCR4 activation, MDSC inhibition, and TGFβ traps, will likely compose the next wave of combination therapies. Key ongoing trials of cetuximab and ICI combination therapy in CRC and SCCHN are summarized in Table 3.

Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, et al.


An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. Oncotarget 2016;7:83359–73.


negative breast cancer cell lines expressing EGFR. Breast Cancer Res Treat 2011;130:465–75.


